Immunotherapies News and Research RSS Feed - Immunotherapies News and Research

Taking ipilimumab, nivolumab drugs may increase risk of developing rheumatologic diseases

Taking ipilimumab, nivolumab drugs may increase risk of developing rheumatologic diseases

Case reports on 13 cancer patients suggest that a small number of cancer patients taking the immunotherapy drugs ipilimumab and nivolumab may be at some higher-than-normal risk of developing autoimmune joint and tissue diseases, including inflammatory arthritis, according to a preliminary study by Johns Hopkins Medicine researchers. [More]
New CAR-based therapy using combined cancer target could be effective for solid tumors

New CAR-based therapy using combined cancer target could be effective for solid tumors

Chimeric antigen receptors (CARs), engineered from a patient's own immune cells, have been successful for treating blood cancers, but using CARs for solid tumors has been limited by side effects to normal tissues containing the protein targeted by the engineered cells. [More]
VUMC researchers aim to decode genetic underpinnings of human immune system

VUMC researchers aim to decode genetic underpinnings of human immune system

Researchers at Vanderbilt University Medical Center this month began recruiting volunteers to participate in a clinical trial aimed at decoding the human "immunome," the genetic underpinnings of the immune system. [More]
Study ignores possibility that drugs, chemicals affect sexes differently

Study ignores possibility that drugs, chemicals affect sexes differently

Many of the medicines we take were only ever tested on men during clinical studies. This poses a distinct danger that females are receiving suboptimal care—and that treatments specifically benefiting women are going undiscovered. [More]
FDG-PET imaging tracks ability of atezolizumab to bolster immunity against NSCLC

FDG-PET imaging tracks ability of atezolizumab to bolster immunity against NSCLC

Non-small cell lung cancers have a collective reputation for not responding very well to chemotherapy. Researchers at the 2016 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) are presenting a means of evaluating an immunotherapy that fights off NSCLC by strengthening a patient's own immune system. [More]
EPFL researchers reprogram TAMs to prevent tumor metastasis

EPFL researchers reprogram TAMs to prevent tumor metastasis

One of the major obstacles with treating cancer is that tumors can conscript the body's immune cells and make them work for them. Researchers at EPFL have now found a way to reclaim the corrupted immune cells, turn them into signals for the immune system to attack the tumor, and even prevent metastasis. [More]
Researchers find link between specific genetic pathway and development of mouth ulcers in lupus patients

Researchers find link between specific genetic pathway and development of mouth ulcers in lupus patients

The results of a study presented today at the European League Against Rheumatism Annual Congress showed for the first time an association between a specific genetic pathway and the development of mouth ulcers in patients with Systemic Lupus Erythematosus (SLE). [More]
Dr. Pinchas Tsukerman earns prestigious Kaye Innovation Award for research on cancer immunotherapy

Dr. Pinchas Tsukerman earns prestigious Kaye Innovation Award for research on cancer immunotherapy

The importance of the body's immune system in protecting against the creation of cancerous tumors has been known for a long time. But despite the existence of a competent immune system, some individuals develop tumors, in part because tumors have ways to evade destructive immunity or induce immune-suppression. [More]
Avoiding allergens could be best approach to prevent food allergies

Avoiding allergens could be best approach to prevent food allergies

Around two million people in Austria suffer from an allergy. 400,000 of them are allergic to birch pollen and have associated food allergies, particularly to apples, peaches, hazelnuts, carrots and celery. According to experts, around 80,000 people are thought to have a primary food allergy in childhood. [More]
Existing immunotherapy drug pembrolizumab shows promise for specific sarcoma subtypes

Existing immunotherapy drug pembrolizumab shows promise for specific sarcoma subtypes

An existing cancer immunotherapy drug reduces tumor size in some types of rare connective tissue cancers, called sarcomas, report researchers at the University of Pittsburgh Cancer Institute. [More]
Combination immunotherapy may be better than one to combat metastatic melanoma

Combination immunotherapy may be better than one to combat metastatic melanoma

A new metastatic melanoma study suggests that a combination of two immunotherapies may be better than one. [More]
Gene dysregulation makes immune therapies less effective against metastatic melanoma

Gene dysregulation makes immune therapies less effective against metastatic melanoma

Patients who don't respond to treatments that use their own immune cells to destroy tumors, called tumor infiltrating lymphocytes, share changes in mechanisms that switch genes on or off in those cells, according to study results presented at the annual meeting of the American Society for Clinical Oncology on June 4 in Chicago. [More]
New mouse model allows researchers to evaluate CD40-antibody drugs effectively

New mouse model allows researchers to evaluate CD40-antibody drugs effectively

Cancer immunotherapies--drugs that work by making a patient's immune system better at spotting and destroying tumor cells--are increasingly generating headlines. A number of these drugs are now being used for the treatment of melanoma, lung, and kidney cancers, and are showing promise in clinical trials with other diseases as well. [More]
TxCell, LIED collaborate to develop CAR-Treg-based cellular immunotherapy for bullous pemphigoid

TxCell, LIED collaborate to develop CAR-Treg-based cellular immunotherapy for bullous pemphigoid

TxCell SA, a biotechnology company developing innovative, personalized cellular immunotherapies using regulatory T cells to treat severe chronic inflammatory and autoimmune diseases, today announces the signature of a strategic R&D collaboration agreement with the Lübeck Institute of Experimental Dermatology, a leading institution in the field of translational research on skin blistering diseases, part of the University of Lübeck in Germany. [More]
Experts urge cancer researchers to use old, obese mice for preclinical immunotherapy studies

Experts urge cancer researchers to use old, obese mice for preclinical immunotherapy studies

Researchers should include laboratory mice that are old and obese in their studies of immunotherapy treatments for cancer, according to a review article by Saint Louis University scientists. [More]
Researchers develop new drugs for melanoma

Researchers develop new drugs for melanoma

Finding new, more effective and personalised treatments for cancer is the challenge of many researchers. A challenge that has been successfully met by a team from Inserm led by Stéphane Rocchi, which has just synthesised and developed new drugs for melanoma. [More]
CGT, CTM CRC collaborate to test patented scaffold technology for commercial scale cell expansion systems

CGT, CTM CRC collaborate to test patented scaffold technology for commercial scale cell expansion systems

The Cell and Gene Therapy Catapult and the CRC for Cell Therapy Manufacturing, the Australian centre for translation of cell therapy technologies, today announce a project to test at scale CTM CRC’s patented scaffold technology. [More]
Researchers find ways to switch on Natural Killer cells to combat cancer

Researchers find ways to switch on Natural Killer cells to combat cancer

Our bodies are constantly and successfully fighting off the development of cells that lead to tumours - but when there is disruption to this process cancer is free to develop. [More]
Ongoing treatment with nivolumab shows benefit in advanced kidney cancer patients

Ongoing treatment with nivolumab shows benefit in advanced kidney cancer patients

Only 12% of kidney cancer patients with advanced disease survive five years after their initial treatment. In a Roswell Park Cancer Institute-led study, scientists report that some patients with advanced kidney cancer who continued to receive a novel immunotherapy drug after their disease progressed saw clinical benefit. [More]
Radiation-immunotherapy combination can help treat melanoma

Radiation-immunotherapy combination can help treat melanoma

Combining radiation treatments with a new generation of immunotherapies is showing promise as a one-two-punch against melanoma, Loyola Medicine researchers report in a review article. [More]
Advertisement
Advertisement